Day: May 23, 2025

 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION,DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE IT IS UNLAWFULTO DO SO Flutter announces the pricing of $1,000 million aggregate principal amount of 5.875% Senior Secured Notes due 2031, €550 million aggregate principal amount of 4.000% Senior Secured Notes due 2031 and £450 million aggregate principal amount of 6.125% Senior Secured Notes due 2031 DUBLIN and TORONTO, May 23, 2025 (GLOBE NEWSWIRE) — Flutter Entertainment plc (“Flutter“) (NYSE:FLUT; LSE:FLTR), today announced the pricing of an offering (the “Offering“) of $1,000 million aggregate principal amount of USD-denominated 5.875% senior secured notes due 2031, €550 million aggregate principal amount of EUR-denominated 4.000% senior secured notes due 2031, and £450 million aggregate principal amount...

PRESS RELEASE AB SCIENCE ANNOUNCES THE SETTLEMENT DELIVERY OF ITS LATEST CAPITAL INCREASE FOR €1.8 MILLION Paris, May 23, 2025, 8am CET AB Science S.A. (the “Company” or “AB Science”, Euronext – FR0010557264 – AB) today announces the settlement and delivery of its capital increase announced on May 20, 2025 for an amount of €1.8 million, subscribed by a limited number of investors. This transaction strengthens the Company’s cash position and enables it to cover its financing needs in 2025 and beyond the next 12 months, taking into account the explanations set out in section 5.2.1.5 (note 2) of the 2024 financial report. About masitinib Masitinib is a novel oral tyrosine kinase inhibitor that is being developed to target mast cells and macrophages, key immune cells, through inhibition of a limited number of kinases. Due to its unique...

ENDEAVOUR ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING 2025 London, 23 May 2025 – Endeavour Mining plc (LSE:EDV, TSX:EDV, OTCQX:EDVMF) (“the Company”) is pleased to announce that all resolutions at yesterday’s annual general meeting (“AGM”) were duly passed by shareholders. All resolutions were taken by poll and the results for the resolutions voted upon at the AGM are set out below:RESOLUTION VOTESFOR % FOR VOTESAGAINST % AGAINST TOTAL VOTES % OF ISC VOTED VOTESWITHHELDORDINARY RESOLUTIONS1. To receive the 2024 Annual Report 176,125,066 99.99% 24,217 0.01% 176,149,283 72.73% 180,9962. To re-elect Alison Baker as a Director 172,530,626 97.86% 3,781,331 2.14% 176,311,957 72.79% 18,3223. To re-elect Patrick Bouisset as a Director 176,089,288 99.87%...

The strategic collaboration with Broad Clinical Labs will explore and develop applications using Roche’s SBX sequencing technology1, with an initial focus on critically ill newborns and their parents. Whole genome sequencing can help diagnose babies with suspected genetic disorders, such as cystic fibrosis and sickle cell disease. This project will explore how this technology could become part of routine clinical practice for newborns, as well as its use in other research applications.Basel, 23 May 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a strategic collaboration with Broad Clinical Labs to develop and pilot groundbreaking applications using Roche’s recently unveiled next-generation sequencing (NGS) Sequencing By Expansion (SBX) technology. This collaboration will focus on harnessing the power of the SBX technology...

Laurent-Perrier Group Tours-sur-Marne, 23 May 2025         Financial press releaseResults for the financial year 2024-2025 Laurent-Perrier: Annual result down, but profitability remains high The financial statements for the 2024-2025 financial year, ended 31 March 2025, were approved by the Management Board at its meeting on 20 May 2025 and reviewed the following day by the Supervisory Board, chaired by Mr Patrick THOMAS. Key consolidated audited financial data:In millions of EurosAt 31 March 2025 Financial year 2023-2024 (N-1)(1 April 2023 –31 March 2024) Financial year2024-2025(1 April 2024 –31 March 2025) Change vs FY N-1Champagne sales 303.5 282.9 – 6.8%Group revenue 312.5 294.4 – 5.8%Operating profit (loss) 95.1 74.4 – 21.8%Operating margin % (*) 31.3% 26.3% – 5.0 ptsNet profit...

Not for distribution to U.S. newswire services or for dissemination in the United States. TORONTO, May 22, 2025 (GLOBE NEWSWIRE) — (TSX: SBC, SBC.PR.A) Brompton Split Banc Corp. (the “Fund”) is pleased to announce it has renewed its at-the-market equity program (“ATM Program”) so that the Fund can issue class A and preferred shares (the “Class A Shares” and “Preferred Shares”, respectively) to the public from time to time, at the Fund’s discretion. This ATM Program replaces the prior program established in April 2023 that has terminated. Any Class A Shares or Preferred Shares sold under the ATM Program will be sold through the Toronto Stock Exchange (the “TSX”) or any other marketplace in Canada on which the Class A Shares and Preferred Shares are listed, quoted or otherwise traded at the prevailing market price at the time of...

SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten public offering of 2,222,222 shares of its common stock at a public offering price of $9.00 per share. In addition, Gyre has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 333,333 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds of the offering to Gyre, before deducting the underwriting discounts and commissions and other offering expenses payable by Gyre, are expected to be approximately $20.0 million. The offering is expected to close on or about May 27, 2025,...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 23, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitinib, ranosidenib, fruquintinib and surufatinib, will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place on May 30 – June 3, 2025 in Chicago, USA. Results from the SACHI China Phase III study of savolitinib in combination with osimertinib in patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation-positive non-small cell lung cancer (“NSCLC”) with MET amplification after disease progression on EGFR inhibitor therapy will be presented at a late breaking oral presentation. SACHI had met the pre-defined primary...